Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of iPSC-CL in Congenital Heart Disease
NCT05647213Phase 1Recruiting
- Sponsor
- HeartWorks
- Start
- Feb 2023
- Primary completion
- Sep 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of iPSC-CL in congenital heart disease (CHD) and heart failure (HF) (2 arms), sponsored by HeartWorks. Primary endpoints: Short term safety at 3 months and Feasibility at 12 months. Started Feb 2023; status: recruiting.
02
Drugs
iPSC-CL
03
Conditions
congenital heart disease (CHD)heart failure (HF)
Beyond the preview
Go deeper on NCT05647213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647213.